Table 6.
Vascular-disrupting agents (VDAs) and developmental status.
| VDAs Name | Company | Stage of Clinical Development | Ref. |
|---|---|---|---|
| Tubulin Binding | |||
| CA4P (fosbretabulin) | Mateon Therapeutics | Phase 2/3 | [3,49] |
| C118P | Sanhome Pharmaceutical | Phase 2 | [128] |
| Combretastatin A4 gold derivative |
University Bayreuth | New formulation under research | [129] |
| Deoxypodophyllotoxin (DPT) | China Pharmaceutical University | New formulation under research | [130] |
| NPI-2358 (plinabulin) | BeyondSpring | Phase 3 | [3] |
| BNC105P | Bionomics | Phase 2 | [3] |
| EPC2407 (crolibulin) | Immune Pharmaceuticals | Phase 1/2 | [127] |
| OXi4503 (CA1P) | Mateon Therapeutics | Phase 1/2 | [3] |
| CKD-516 | Chong Kun Dang Pharmaceutical |
Phase 1 | [3,131] |
| MN-029 | Medicinova | Phase 1 | [3] |
| ENMD-1198 | EntreMed | Phase 1 | [132] |
| C9 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | New formulation under research | [133] |
| Phenyl-3-(2-chloroethyl) urea (CEU) | IMOTEP Inc. | New formulation under research | [134] |
| BPR0C261 | National Health Research Institutes, Taiwan | New formulation under research | [135] |
| BPR0L075 | National Health Research Institutes, Taiwan | New formulation under research | [136] |
| IMC-038525 | ImClone Systems | New formulation under research | [137] |
| ABT-751 | Abbott | Phase 2 | [3] |
| AVE8062 (ombrabulin) | Sanofi-Aventis | Development terminated | [3] |
| CYT997 (lexibulin) | Gilead | Development terminated | [3] |
| Dolastatin-10 | Marine Biotech | Phase 2 | [3] |
| MPC-6827 (verubulin, Azixa) | Myrexis | Phase 2 | [3] |
| TZT-1027 (soblidotin) | Daiichi-Sankyo | Phase 2 | [3] |
| ZD6126 (ANG453) | AstraZeneca | Phase 2 | [3] |
| Flavonoids | |||
| ASA404 or DMXAA | Antisoma | Phase 3 | [3] |